Biblio Discovery — Demo Discovery Service

15 hasil untuk "Linjiang Tong"

Menampilkan 1–15 · 0,66 detik · RSS

  1. Artikel Jurnal Teks lengkap

    The Marine-Derived Oligosaccharide Sulfate (MdOS), a Novel Multiple Tyrosine Kinase Inhibitor, Combats Tumor Angiogenesis both In Vitro and In Vivo

    Jingui Ma; Xianliang Xin; Linghua Meng dkk.

    PLoS ONE, Vol. 3 No. 11 · 2008 · Inggris · PLOS Scopus

    Despite the emerging success of multi-targeted protein tyrosine kinase (PTK) inhibitors in cancer therapy, significant side effects and resistance concerns seems to be avoided unlikely. The aim of the present study was to identify novel multi-targeting PTK inhibitors. The kinase enzymatic…

    Juga tersedia di: DOAJ

  2. Artikel Jurnal

    Design, synthesis and pharmacological evaluation of 1,2,3,4-tetrahydrobenzofuro[2,3-c]pyridine derivatives as p21-activated kinase 4 inhibitors for treatment of pancreatic cancer

    Yang Li; Yan Fang; Xiaoyu Chen dkk.

    Acta Pharmaceutica Sinica B, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    The p21-activated kinase 4 (PAK4), a key regulator of malignancy, is negatively correlated with immune infiltration and has become an emergent drug target of cancer therapy. Given the lack of high efficacy PAK4 inhibitors, we herein reported the identification of a novel inhibitor 13 bearing a…

  3. Artikel Jurnal

    Design, Synthesis, and Evaluation of Ribose-Modified Anilinopyrimidine Derivatives as EGFR Tyrosine Kinase Inhibitors

    Xiuqin Hu; Disha Wang; Yi Tong dkk.

    Frontiers in Chemistry, Vol. 5 · 2017 · Inggris · DOAJ Scopus

    The synthesis of a series of ribose-modified anilinopyrimidine derivatives was efficiently achieved by utilizing DBU or tBuOLi-promoted coupling of ribosyl alcohols with 2,4,5-trichloropyrimidine as key step. Preliminary biological evaluation of this type of compounds as new EGFR tyrosine kinase…

  4. Artikel Jurnal Teks lengkap

    AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

    Hua Xie; Liping Lin; Linjiang Tong dkk.

    PLoS ONE, Vol. 6 No. 7 · 2011 · Inggris · PLOS Scopus

    Despite the initial response to the reversible, ATP-competitive quinazoline inhibitors that target ErbB-family, such a subset of cancer patients almost invariably develop resistance. Recent studies have provided compelling evidence that irreversible ErbB inhibitors have the potential to override…

    Juga tersedia di: DOAJ

  5. Artikel Jurnal

    Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma

    Wenhao Shi; Haotian Tang; Linjiang Tong dkk.

    Cancer Cell International, Vol. 25 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Melanoma is notorious for its aggressive growth, metastatic spread, and heterogeneous response to therapy across BRAF (B-Raf proto-oncogene, serine/threonine kinase) genotypes. While BRAF inhibitors improve outcomes in V600E-mutant tumors, their benefit is limited in wild-type…

  6. Artikel Jurnal

    Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

    Tao Zhang; Rong Qu; Shingpan Chan dkk.

    Molecular Cancer, Vol. 19 No. 1 · 2020 · Inggris · DOAJ Scopus

    Abstract Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven by the EGFR T790M mutation. The discovery of third-generation EGFR…

  7. Artikel Jurnal

    ASK120067 potently suppresses B-cell or T-cell malignancies in vitro and in vivo by inhibiting BTK and ITK

    Peiran Song; Gang Bai; Shingpan Chan dkk.

    Frontiers in Pharmacology, Vol. 13 · 2022 · Inggris · DOAJ Scopus

    Hyperactivation of Bruton’s tyrosine kinase (BTK) or interleukin-2-inducible T cell kinase (ITK) has been attributed to the pathogenesis of B-cell lymphoma or T-cell leukemia, respectively, which suggests that Bruton’s tyrosine kinase and interleukin-2-inducible T cell kinase are critical targets…

  8. Artikel Jurnal

    Sphingosine‐1‐Phosphate Receptor 3 Confers Tumor Metastasis in Lung Cancer Resistant to Third‐Generation EGFR Inhibitor

    Mengzhen Lai; Jiaying Chen; Ye Qin dkk.

    MedComm, Vol. 7 No. 5 · 2026 · Inggris · DOAJ Scopus

    ABSTRACT The third‐generation EGFR tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has significantly improved the survival in EGFR‐mutant lung cancer patients. Our team developed limertinib (ASK120067), a novel third‐generation EGFR inhibitor with remarkable antitumor effects, which has been…

  9. Artikel Jurnal

    Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

    Yingqiang Liu; Zhengsheng Zhan; Zhuang Kang dkk.

    Acta Pharmaceutica Sinica B, Vol. 13 No. 12 · 2023 · Inggris · DOAJ Scopus

    Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults and is poorly controlled. Previous studies have shown that both macrophages and angiogenesis play significant roles in GBM progression, and co-targeting of CSF1R and VEGFR is likely to be an effective strategy for…

  10. Artikel Jurnal

    Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation

    Tao Zhang; Zilu Pan; Jing Gao dkk.

    Signal Transduction and Targeted Therapy, Vol. 9 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Third-generation EGFR tyrosine kinase inhibitors (TKIs), exemplified by osimertinib, have demonstrated promising clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Our previous work has identified ASK120067 as a novel third-generation EGFR TKI with remarkable…